Lupus erythematosus
☆ Ann an toraidhean 2022 Stiftung Warentest às a’ Ghearmailt, cha robh sàsachd luchd-cleachdaidh le ModelDerm ach beagan nas ìsle na le co-chomhairlean telemedicine pàighte.
Tha e a’ nochdadh mar erythema beagan purpaidh.
Am broth dealan-dè a bhios mar as trice a’ nochdadh air an aghaidh.
References
Tha comharrachadh agus seòrsachadh cutaneous lupus erythematosus (CLE) a’ togail dhùbhlain breithneachaidh, ga eadar-dhealachadh bho systemic lupus erythematosus le com-pàirt craiceann. Tha sgrùdaidhean o chionn ghoirid a’ tilgeil solas air factaran ginteil, àrainneachdail agus imdhun-eòlach a tha mar bhunait air CLE. Tha inntrigeadh dhrogaichean gu sònraichte air nochdadh mar aon de na brosnachaidhean as cudromaiche airson CLE. Tha làimhseachadh a’ toirt a-steach leigheasan gnàthach is siostamach, a’ toirt a-steach bith-eòlas gealltanach (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , le èifeachd air a nochdadh ann an deuchainnean clionaigeach.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Tha Cutaneous lupus erythematosus (CLE) a’ còmhdach diofar chùisean craiceann, cuid dhiubh a dh’ fhaodadh a bhith co-cheangailte ri duilgheadasan slàinte nas fharsainge. Tha e air a roinn ann an diofar sheòrsachan, leithid acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . Tha CCLE a’ toirt a-steach discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Tha Lupus erythematosus na bhuidheann de ghalaran fèin-dìon a bheir buaidh air diofar phàirtean den bhodhaig. Bidh cuid de sheòrsan, leithid systemic lupus erythematosus (SLE) , a’ toirt buaidh air grunn bhuill-bodhaig, agus cuid eile, leithid cutaneous lupus erythematosus (CLE) , sa mhòr-chuid a’ toirt buaidh air a’ chraiceann. Bidh sinn a’ seòrsachadh diofar sheòrsaichean CLE stèidhichte air measgachadh de shoidhnichean clionaigeach, sgrùdadh clò, agus deuchainnean fala, ach tha tòrr eadar-dhealachaidh eadar daoine fa-leth. Bidh duilgheadasan craiceann gu tric a’ tighinn am bàrr mar thoradh air factaran mar a bhith fosgailte do sholas na grèine, smocadh, no cungaidhean sònraichte.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Chan eil adhbhar lupus erythematosus soilleir. Am measg chàraid co-ionann, ma tha buaidh air aon dhiubh tha teansa 24% ann gum bi am fear eile cuideachd. Thathas cuideachd a’ creidsinn gu bheil hormonaichean gnè boireann, solas na grèine, smocadh, easbhaidh vitimín D, agus galairean sònraichte ag àrdachadh a ’chunnart.
Faodaidh làimhseachadh a bhith a’ toirt a-steach NSAIDs, corticosteroids, immunosuppressants, hydroxychloroquine, agus methotrexate. Ged a tha corticosteroids èifeachdach, bidh cleachdadh fad-ùine a’ leantainn gu fo-bhuaidhean.